

Toyomasa Katagiri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/41542/publications.pdf>

Version: 2024-02-01

76
papers

3,365
citations

159358

30
h-index

155451

55
g-index

79
all docs

79
docs citations

79
times ranked

5518
citing authors

#	ARTICLE	IF	CITATIONS
1	Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases. <i>Nature Genetics</i> , 2020, 52, 669-679.	9.4	304
2	Predicting Response to Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Neoadjuvant Chemotherapy for Bladder Cancers through Genome-Wide Gene Expression Profiling. <i>Clinical Cancer Research</i> , 2005, 11, 2625-2636.	3.2	228
3	Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. <i>Nature Communications</i> , 2018, 9, 4083.	5.8	179
4	PDZ-Binding Kinase/T-LAK Cell-Originated Protein Kinase, a Putative Cancer/Testis Antigen with an Oncogenic Activity in Breast Cancer. <i>Cancer Research</i> , 2006, 66, 9186-9195.	0.4	164
5	Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family. <i>Breast Cancer Research</i> , 2007, 9, R17.	2.2	150
6	Critical Roles of Mucin 1 Glycosylation by Transactivated Polypeptide N-Acetylgalactosaminyltransferase 6 in Mammary Carcinogenesis. <i>Cancer Research</i> , 2010, 70, 2759-2769.	0.4	146
7	Therapeutic potential of antibodies against FZD10, a cell-surface protein, for synovial sarcomas. <i>Oncogene</i> , 2005, 24, 6201-6212.	2.6	116
8	Ubiquitination and Downregulation of BRCA1 by Ubiquitin-Conjugating Enzyme E2T Overexpression in Human Breast Cancer Cells. <i>Cancer Research</i> , 2009, 69, 8752-8760.	0.4	106
9	Oncogenic Role of MPHOSPH1, a Cancer-Testis Antigen Specific to Human Bladder Cancer. <i>Cancer Research</i> , 2007, 67, 3276-3285.	0.4	104
10	Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis. <i>International Journal of Oncology</i> , 2013, 42, 478-506.	1.4	104
11	Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells. <i>Cancer Science</i> , 2007, 98, 174-181.	1.7	97
12	Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis. <i>Cancer Science</i> , 2008, 99, 62-70.	1.7	94
13	Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy. <i>Cancer Research</i> , 2005, 65, 4817-4826.	0.4	90
14	Genome-Wide Profiling of Gene Expression in 29 Normal Human Tissues with a cDNA Microarray. <i>DNA Research</i> , 2002, 9, 35-45.	1.5	82
15	Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. <i>Cancer Science</i> , 2007, 98, 113-117.	1.7	68
16	Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. <i>Cancer Science</i> , 2008, 99, 432-440.	1.7	68
17	Critical roles of T-LAK cell-originated protein kinase in cytokinesis. <i>Cancer Science</i> , 2010, 101, 403-411.	1.7	68
18	Xanthohumol suppresses oestrogen-signalling in breast cancer through the inhibition of BIG3-PHB2 interactions. <i>Scientific Reports</i> , 2014, 4, 7355.	1.6	68

#	ARTICLE	IF	CITATIONS
19	Targeting BIG3- β -catenin interaction to overcome tamoxifen resistance in breast cancer cells. <i>Nature Communications</i> , 2013, 4, 2443.	5.8	63
20	Activation of an estrogen/estrogen receptor signaling by BIG3 through its inhibitory effect on nuclear transport of β -catenin/REB1 in breast cancer. <i>Cancer Science</i> , 2009, 100, 1468-1478.	1.7	54
21	Critical roles of LGN/GSK3 β phosphorylation by PKA/TOPK in cell division of breast cancer cells. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 861-872.	1.5	47
22	Present status and future perspective of peptide-based vaccine therapy for urological cancer. <i>Cancer Science</i> , 2018, 109, 550-559.	1.7	42
23	A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. <i>BMC Cancer</i> , 2018, 18, 646.	1.1	42
24	Oncogenic role of NALP7 in testicular seminomas. <i>Cancer Science</i> , 2004, 95, 949-954.	1.7	41
25	Involvement of β -catenin domain containing 2 overexpression in breast carcinogenesis. <i>Cancer Science</i> , 2009, 100, 1443-1450.	1.7	41
26	Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. <i>International Journal of Oncology</i> , 2004, 25, 797-819.	1.4	36
27	Inverse correlation of the up-regulation of FZD10 expression and the activation of β -catenin in synchronous colorectal tumors. <i>Cancer Science</i> , 2009, 100, 405-412.	1.7	35
28	DDX31 Regulates the p53-MDM2 Pathway and rRNA Gene Transcription through Its Interaction with NPM1 in Renal Cell Carcinomas. <i>Cancer Research</i> , 2012, 72, 5867-5877.	0.4	35
29	Early Growth Response 4 Is Involved in Cell Proliferation of Small Cell Lung Cancer through Transcriptional Activation of Its Downstream Genes. <i>PLoS ONE</i> , 2014, 9, e113606.	1.1	34
30	Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. <i>International Journal of Oncology</i> , 2016, 49, 471-478.	1.4	32
31	Identification of PDZK4, a novel human gene with PDZ domains, that is upregulated in synovial sarcomas. <i>Oncogene</i> , 2004, 23, 5551-5557.	2.6	31
32	Identification of novel epigenetically inactivated gene PAMR1 in breast carcinoma. <i>Oncology Reports</i> , 2015, 33, 267-273.	1.2	31
33	β -particle therapy for synovial sarcoma in the mouse using an ^{211}At -labeled antibody against frizzled homolog 10. <i>Cancer Science</i> , 2018, 109, 2302-2309.	1.7	31
34	A DDX31/Mutant p53/EGFR Axis Promotes Multistep Progression of Muscle-Invasive Bladder Cancer. <i>Cancer Research</i> , 2018, 78, 2233-2247.	0.4	30
35	Trans-omics Impact of Thymoproteasome in Cortical Thymic Epithelial Cells. <i>Cell Reports</i> , 2019, 29, 2901-2916.e6.	2.9	27
36	Allelic loss at 1p34, 13q12, 17p13.3, and 17q21.1 correlates with poor postoperative prognosis in breast cancer. <i>Cancer Research</i> , 1999, 59, 134-141.		26

#	ARTICLE	IF	CITATIONS
37	Identification of a significant association of a single nucleotide polymorphism in TNXB with systemic lupus erythematosus in a Japanese population. <i>Journal of Human Genetics</i> , 2008, 53, 64-73.	1.1	26
38	Critical involvement of RQCD1 in the EGFR-Akt pathway in mammary carcinogenesis. <i>International Journal of Oncology</i> , 2010, 37, 1085-93.	1.4	23
39	Significant association between high serum CCL5 levels and better disease-free survival of patients with early breast cancer. <i>Cancer Science</i> , 2020, 111, 209-218.	1.7	23
40	Multiplex Mutation Screening of the BRCA1 Gene in 1000 Japanese Breast Cancers. <i>Japanese Journal of Cancer Research</i> , 1998, 89, 12-16.	1.7	22
41	Involvement of RQCD1 overexpression, a novel cancer-testis antigen, in the Akt pathway in breast cancer cells. <i>International Journal of Oncology</i> , 2009, 35, 673-81.	3.9	21
42	Sex- and age-dependent gene expression in human liver: An implication for drug-metabolizing enzymes. <i>Drug Metabolism and Pharmacokinetics</i> , 2017, 32, 100-107.	1.1	20
43	Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on radiosensitivity. <i>Annals of Nuclear Medicine</i> , 2009, 23, 479-485.	1.2	19
44	BIG3 Inhibits the Estrogen-Dependent Nuclear Translocation of PHB2 via Multiple Karyopherin-Alpha Proteins in Breast Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0127707.	1.1	19
45	Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers. <i>Oncotarget</i> , 2017, 8, 26122-26128.	0.8	19
46	Involvement of C12orf32 overexpression in breast carcinogenesis. <i>International Journal of Oncology</i> , 2010, 37, 861-7.	1.4	17
47	High Serum Levels of Interleukin-18 Are Associated With Worse Outcomes in Patients With Breast Cancer. <i>Anticancer Research</i> , 2019, 39, 5009-5018.	0.5	17
48	Critical Role of Estrogen Receptor Alpha O-Glycosylation by N-Acetylgalactosaminyltransferase 6 (GALNT6) in Its Nuclear Localization in Breast Cancer Cells. <i>Neoplasia</i> , 2018, 20, 1038-1044.	2.3	15
49	Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER+, and HER2+ Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 197-203.	1.1	14
50	A-kinase anchoring protein BIG3 coordinates oestrogen signalling in breast cancer cells. <i>Nature Communications</i> , 2017, 8, 15427.	5.8	14
51	Protein kinase A inhibition facilitates the antitumor activity of xanthohumol, a valosin-containing protein inhibitor. <i>Cancer Science</i> , 2017, 108, 785-794.	1.7	13
52	Overexpression of C16orf74 is involved in aggressive pancreatic cancers. <i>Oncotarget</i> , 2017, 8, 50460-50475.	0.8	12
53	Involvement of B3GALNT2 overexpression in the cell growth of breast cancer. <i>International Journal of Oncology</i> , 2014, 44, 427-434.	1.4	11
54	Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer. <i>Cancer Science</i> , 2015, 106, 550-558.	1.7	11

#	ARTICLE	IF	CITATIONS
55	Stapled BIG3 helical peptide ERAP potentiates anti-tumour activity for breast cancer therapeutics. <i>Scientific Reports</i> , 2017, 7, 1821.	1.6	11
56	ERAD components Derlin-1 and Derlin-2 are essential for postnatal brain development and motor function. <i>IScience</i> , 2021, 24, 102758.	1.9	11
57	FZD10-targeted 125 I-radioimmunotherapy with 225 Ac-labeled OTSA101 achieves complete remission in a synovial sarcoma model. <i>Cancer Science</i> , 2022, 113, 721-732.	1.7	11
58	Identification of an HLA-A2-Restricted Epitope Peptide Derived from Hypoxia-Inducible Protein 2 (HIG2). <i>PLoS ONE</i> , 2014, 9, e85267.	1.1	10
59	The prediction models for postoperative overall survival and disease-free survival in patients with breast cancer. <i>Cancer Medicine</i> , 2017, 6, 1627-1638.	1.3	10
60	The survival and proliferation of osteosarcoma cells are dependent on the mitochondrial BIG3-PHB2 complex formation. <i>Cancer Science</i> , 2021, 112, 4208-4219.	1.7	10
61	Brefeldin A-inhibited guanine nucleotide-exchange protein 3 (BIG3) is predicted to interact with its partner through an ARM-type α -helical structure. <i>BMC Research Notes</i> , 2014, 7, 435.	0.6	9
62	Identification of two novel breast cancer loci through large-scale genome-wide association study in the Japanese population. <i>Scientific Reports</i> , 2019, 9, 17332.	1.6	9
63	Functional genomics for breast cancer drug target discovery. <i>Journal of Human Genetics</i> , 2021, 66, 927-935.	1.1	9
64	The GALNT6-LGALS3BP axis promotes breast cancer cell growth. <i>International Journal of Oncology</i> , 2020, 56, 581-595.	1.4	9
65	Frequent downregulation of LRRC26 by epigenetic alterations is involved in the malignant progression of triple-negative breast cancer. <i>International Journal of Oncology</i> , 2018, 52, 1539-1558.	1.4	8
66	High levels at baseline of serum pyridinoline crosslinked carboxyterminal telopeptide of type I collagen are associated with worse prognosis for breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 521-531.	1.1	6
67	Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18 F-deoxyglucose levels on positron emission tomography for breast cancers. <i>PLoS ONE</i> , 2017, 12, e0184508.	1.1	6
68	Molecular targeting of cell-permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferation. <i>Oncotarget</i> , 2017, 8, 113662-113672.	0.8	5
69	Biophysical characterization of the breast cancer-related BIG3-PHB2 interaction: Effect of non-conserved loop region of BIG3 on the structure and the interaction. <i>Biochemical and Biophysical Research Communications</i> , 2019, 518, 183-189.	1.0	3
70	A Commentary on Analysis of ZNF350/ZBRK1 promoter variants and breast cancer susceptibility in non-BRCA1/2 French Canadian breast cancer families. <i>Journal of Human Genetics</i> , 2013, 58, 58-58.	1.1	2
71	A prospective study to examine the accuracies and efficacies of prediction systems for response to neoadjuvant chemotherapy for muscle invasive bladder cancer. <i>Oncology Letters</i> , 2018, 16, 5775-5784.	0.8	2
72	Activation of an Estrogen/ Estrogen Receptor Signaling by BIG3 Through Its Inhibitory Effect on Nuclear Transport of PHB2/REA in Breast Cancer. <i>Nature Precedings</i> , 2009, , .	0.1	1

#	ARTICLE	IF	CITATIONS
73	SYNFRIZZ: A first-in-human (FIH) study of a radiolabeled monoclonal antibody (Mab) targeting frizzled homolog 10 (FZD10) in patients (pts) with advanced synovial sarcomas (SyS).. Journal of Clinical Oncology, 2017, 35, 11054-11054.	0.8	1
74	Validation Study on the Prediction of Response to Imatinib Mesylate in Chronic Myeloid Leukemia (CML) Patients by Genome-Wide cDNA Microarray Analysis.. Blood, 2004, 104, 2946-2946.	0.6	0
75	Development of anti-breast cancer peptides using stapling technology. Drug Delivery System, 2020, 35, 200-211.	0.0	0
76	Regulation of Gene Expression via Protein Oxidation. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2022, 95, 1-SS-57.	0.0	0